## <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

#### **Materials**

Antibodies	Yes (indicate where	n/a
For commercial reagents, provide supplier		No antibodies were used.
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where	n/a
Cell lines: Provide species information, strain.	The 'Method'section,	
Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number,	paragraph 2	
OR RRID		
Primary cultures: Provide species, strain, sex of		No primary cultures were performed
origin, genetic modification status.		

Experimental animals	Yes (indicate where	n/a
<b>Laboratory animals:</b> Provide species, strain, sex, age, genetic modification status. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID		No laboratory animals were involved.
Animal observed in or captured from the field: Provide species, sex and age where possible		No animals were observed in or captured from the field
Model organisms: Provide Accession number in repository (where relevant) OR RRID		No model organisms were used

Plants and microbes	Yes (indicate where	n/a
Plants: provide species and strain, unique accession		No plants were used
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique		No microbes were used
accession number if available, and source		
,		

Human research participants	Yes (indicate where	n/a
Identify authority granting ethics approval (IRB or		The ethics approval was waived by the
equivalent committee(s), provide reference number		ethical commitee
for approval.		
Provide statement confirming informed consent		The informed consent was waived due
obtained from study participants.		to the anonymous data and non-
		intervention feature of the study.
Report on age and sex for all study participants.		The study endpoints were not relevant
		to sex and age of the participants.

### **Design**

Study protocol	Yes (indicate where	n/a
For clinical trials, provide the trial registration		This study is not a clinical trial.
number <b>OR</b> cite DOI in manuscript.		
Laboratory protocol	Voc /indicate where	n/2
Provide DOI or other citation details if detailed step-	Yes (indicate where	n/a
by-step protocols are available.		No detailed step-by-step
by-step protocols are available.		protocol has been pre-defined
Experimental study design (statistics details)	Yes (indicate where	n/a
State whether and how the following have been		
done, <b>or</b> if they were not carried out.		
Sample size determination		Sample size was not calculated
		based on analytical method.
Randomisation		No randomisation was
		performed
Blinding		No blinding was performed
Inclusion/exclusion criteria		No inclusion/exclusion criteria
		was pre-defined
Sample definition and in-laboratory replication	Yes (indicate where	n/a
State number of times the experiment was		The experiment was not
replicated in laboratory		replicated in laboratory
Define whether data describe technical or biological		There were not technical or
replicates		biological replicates
Ethics	Yes (indicate where	n/a
Studies involving human participants: State details of		The ethics approval was
authority granting ethics approval (IRB or equivalent		waived by the ethical
committee(s), provide reference number for		commitee
approval.		
Studies involving experimental animals: State details		No experimental animals were
of authority granting ethics approval (IRB or		involved
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		The relevant permits were not
relevant permits obtained, provide details of		required for specimen and field
authority approving study; if none were required,		samples due to the anonymous
explain why.		data.
Dual Use Research of Concern (DURC)	Yes (indicate where	n/a
If study is subject to dual use research of concern,	. 55 (maioate where	This study is not dual use
state the authority granting approval and reference		research
number for the regulatory approval		, cocaron

# **Analysis**

Attrition	Yes (indicate where	n/a
State if sample or data point from the analysis is	The 'Method'section,	The criteria for exclusion were
excluded, and whether the criteria for exclusion were	paragraph 2	not determined and specified
determined and specified in advance.		in advance.

Statistics	Yes (indicate where	n/a
Describe statistical tests used and justify choice of	The 'Method'section,	
tests.	paragraph 3-4	

Data Availability	Yes (indicate where	n/a
State whether newly created datasets are available,		No dataset was newly created
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession		The data are not publicly
number in repository or DOI or URL.		available.
If publicly available data are reused, provide		No publicly available data were
accession number in repository or DOI or URL, where		reused
possible.		

Code Availability	Yes (indicate where	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		No code or software was newly generated
If code is publicly available, provide accession number in repository, or DOI or URL.		No code or software was newly generated

# Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: <a href="https://dx.doi.org/10.21037/atm-22-486">https://dx.doi.org/10.21037/atm-22-486</a>